睿知中国医院研究地图
候选清单

重庆大学

Chongqing University

重庆大学或医疗集团

名字里带这所大学的医院合在一起算,再加上只署大学名称的论文和试验。

只反映研究活动,不代表医疗水平,也不是医疗建议。 使用说明

鼻咽癌

Nasopharyngeal carcinoma
0.7%中国的鼻咽癌研究论文,每100篇由它牵头的不到1篇

2021–2025年中国大陆共有 2,375 篇该病的 PubMed 英文论文,这里牵头了其中 17 篇(第一或最后作者的第一单位是这里)。

横条是和占比最高的机构(23.4%)相比。

打开这条 PubMed 检索

牵头的开放试验
1
牵头的研究论文
17
牵头的试验
5
占中国试验的比例
0.8%
占全球论文的比例
0.5%
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
研究主题影像与人工智能放疗技术诱导/同步化疗

计入的医院

  1. 重庆大学附属肿瘤医院14
  2. 重庆大学附属中心医院(重庆市人民医院)3

2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。

牵头的论文5
  1. A Randomized, Multicenter, Phase 2 Trial of Camrelizumab With or Without Metastasis-directed Stereotactic Body Radiation Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma.2025International journal of radiation oncology, biology, physicsRCT
  2. Evaluation of the clinical efficacy and safety of Zhuhuang Powder combined with Qingyan Mixture in the prevention and treatment of radiation-induced oral mucositis: A retrospective cohort study.2025Medicine免费全文
  3. A Practical Online Dynamic Nomogram to Predict the Progression-Free Survival in Nasopharyngeal Carcinoma.2025Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  4. Prediction of induction chemotherapy response in locoregionally advanced nasopharyngeal carcinoma based on three pretreatment non-Gaussian diffusion MRI models.2025BMC medical imaging免费全文
  5. Evaluation of induction chemotherapy response using multiphasic dual-energy CT in nasopharyngeal carcinoma.2025European radiology
ClinicalTrials.gov 上的试验6
  1. Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.正在招募NCT06059261牵头方II期2026-02 启动
  2. A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors即将招募NCT07818486研究中心I/II期2026-09 启动
  3. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.正在招募NCT07258979研究中心I/II期2025-11 启动
  4. Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC正在招募NCT07303023研究中心III期2025-09 启动
  5. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response正在招募NCT06239727研究中心III期2024-03 启动
  6. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors正在招募NCT05956587研究中心II期2024-01 启动

PubMed 检索ClinicalTrials.gov

食管鳞状细胞癌

Oesophageal squamous cell carcinoma
0.2%中国的食管鳞癌研究论文,每100篇由它牵头的不到1篇

2021–2025年中国大陆共有 2,923 篇该病的 PubMed 英文论文,这里牵头了其中 6 篇(第一或最后作者的第一单位是这里)。

横条是和占比最高的机构(6.9%)相比。

打开这条 PubMed 检索

牵头的开放试验
1
牵头的研究论文
6
牵头的试验
1
占中国试验的比例
0.2%
占全球论文的比例
0.1%
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 1120242025: 222025
研究主题影像与人工智能新辅助与综合治疗放疗

这些论文过半是实验室或动物研究。

计入的医院

  1. 重庆大学附属肿瘤医院4
  2. 重庆市沙坪坝区人民医院 计入集团统计1
  3. 重庆大学附属三峡医院 计入集团统计1

2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。

牵头的论文5
  1. Influence of radiotherapy interruption on esophageal cancer with intensity-modulated radiotherapy: a retrospective study.2024BMC cancer免费全文
  2. Quantitative parameters derived from dual-energy computed tomography for the preoperative prediction of early recurrence in patients with esophageal squamous cell carcinoma.2023European radiology
  3. IL2RB Remodels the Immune Microenvironment and Promotes the Progression of Esophageal Squamous Cell Carcinoma.2025Annals of clinical and laboratory science
  4. Effect of tristetraprolin on esophageal squamous cell carcinoma cell proliferation.2025Tissue & cell
  5. Exosomal PIK3CB promotes PD-L1 expression and malignant transformation in esophageal squamous cell carcinoma.2023Medical oncology (Northwood, London, England)
ClinicalTrials.gov 上的试验6
  1. An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma正在招募NCT07080437牵头方2021-03 启动
  2. SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma正在招募NCT07700667研究中心II期2026-08 启动
  3. A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors已终止NCT05427396研究中心I期2022-07 启动
  4. A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)进行中,不再招募NCT05094336研究中心I/II期2022-02 启动
  5. JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy状态不明NCT05164848研究中心I期2021-12 启动
  6. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy已完成NCT04543617研究中心III期2020-09 启动

PubMed 检索ClinicalTrials.gov

肝细胞癌

Hepatocellular carcinoma
0.6%中国的肝细胞癌研究论文,每100篇由它牵头的不到1篇

2021–2025年中国大陆共有 14,765 篇该病的 PubMed 英文论文,这里牵头了其中 84 篇(第一或最后作者的第一单位是这里)。

横条是和占比最高的机构(5.5%)相比。

打开这条 PubMed 检索

牵头的开放试验
0
牵头的研究论文
84
牵头的试验
1
占中国试验的比例
0.07%
占全球论文的比例
0.3%
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 442025
研究主题影像、人工智能与早期发现免疫与靶向药物复发与预后

这些论文过半是实验室或动物研究。

计入的医院

  1. 重庆大学附属肿瘤医院23
  2. Chongqing University Jiangjin Hospital11
  3. 重庆大学附属中心医院(重庆市人民医院) 计入集团统计7
  4. 重庆大学附属三峡医院 计入集团统计3
  5. 重庆市涪陵中心医院 计入集团统计1
  6. Cancer Hospital, Chongqing University1

2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。

牵头的论文5
  1. Intermittent Pringle maneuver combined with controlled low Central venous pressure prolongs hepatic hilum occlusion time in patients with hepatocellular carcinoma complicated by post hepatitis B cirrhosis: a randomized c2023Scandinavian journal of gastroenterologyRCT
  2. Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression.2025Journal of hepatology
  3. PINK1 dysfunction in hepatocellular carcinoma fosters immune evasion and disease progression by promoting neutrophil infiltration.2025Journal for immunotherapy of cancer免费全文
  4. The Value of Machine Learning-based Radiomics Model Characterized by PET Imaging with 68Ga-FAPI in Assessing Microvascular Invasion of Hepatocellular Carcinoma.2025Academic radiology
  5. Efficacy of radiotherapy combined with hepatic arterial infusion chemotherapy, TKI and ICI for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study.2025Abdominal radiology (New York)
ClinicalTrials.gov 上的试验6
  1. First in Human Study of SIM0610 in Solid Tumors正在招募NCT07348211研究中心I期2026-01 启动
  2. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  3. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  4. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  5. Comprehensive Prognostic Model: The Study Introduces a Novel Prognostic Model That Incorporates a Wide Range of Clinical and Laboratory Variables, Providing a More Holistic Approach to Predicting Overall Survival in HCC Patients已完成NCT06550739牵头方2019-01 启动
  6. A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma已终止NCT05653427研究中心II期2022-12 启动

PubMed 检索ClinicalTrials.gov

胃癌

Stomach cancer
0.3%中国的胃癌研究论文,每100篇由它牵头的不到1篇

2021–2025年中国大陆共有 9,782 篇该病的 PubMed 英文论文,这里牵头了其中 29 篇(第一或最后作者的第一单位是这里)。

横条是和占比最高的机构(3.9%)相比。

打开这条 PubMed 检索

牵头的开放试验
0
牵头的研究论文
29
牵头的试验
0
占中国试验的比例
0.0%
占全球论文的比例
0.1%
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 2220242025: 112025
研究主题腹膜转移与晚期手术影像与人工智能

计入的医院

  1. 重庆大学附属肿瘤医院15
  2. 重庆大学附属三峡医院 计入集团统计4
  3. 重庆大学附属三峡医院 计入集团统计2
  4. 重庆市急救医疗中心 计入集团统计2
  5. Chongqing Emergency Medical Center1
  6. 重庆大学附属三峡医院 计入集团统计1

2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。

牵头的论文5
  1. Magnifying image-enhanced endoscopy-only mode boosted early cancer diagnostic efficiency: a multicenter randomized controlled trial.2023Gastrointestinal endoscopyRCT
  2. Disruption of KDM4C-ALDH1A3 feed-forward loop inhibits stemness, tumorigenesis and chemoresistance of gastric cancer stem cells.2021Signal transduction and targeted therapy免费全文
  3. Robotic vs. laparoscopic gastrectomy for patients with locally advanced gastric cancer: a meta-analysis of randomized controlled trials and propensity-score-matched studies.2025International journal of surgery (London, England)
  4. A Retrospective Observational Study of Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer and Colorectal Cancer From a Single Center in the Recent 5 years.2024Cancer control : journal of the Moffitt Cancer Center免费全文
  5. Development and validation of a multi-parameter nomogram for venous thromboembolism in gastric cancer patients: a retrospective analysis.2024PeerJ免费全文
ClinicalTrials.gov 上的试验6
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  2. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors正在招募NCT07070232研究中心I/II期2025-08 启动
  3. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  4. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  5. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)进行中,不再招募NCT06356311研究中心III期2024-05 启动
  6. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动

PubMed 检索ClinicalTrials.gov

肝母细胞瘤

Hepatoblastoma
1.3%中国的肝母细胞瘤研究论文,每100篇约有1篇由它牵头 2021年后新出现

2021–2025年中国大陆共有 154 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。

横条是和占比最高的机构(13.6%)相比。

打开这条 PubMed 检索

牵头的开放试验
0
牵头的研究论文
2
牵头的试验
0
占中国试验的比例
0.0%
占全球论文的比例
0.4%
每年牵头的论文数
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

PubMed 检索ClinicalTrials.gov

骨肉瘤

Osteosarcoma
0.3%中国的骨肉瘤研究论文,每100篇由它牵头的不到1篇

2021–2025年中国大陆共有 2,257 篇该病的 PubMed 英文论文,这里牵头了其中 7 篇(第一或最后作者的第一单位是这里)。

横条是和占比最高的机构(4.3%)相比。

打开这条 PubMed 检索

牵头的开放试验
0
牵头的研究论文
7
牵头的试验
0
占中国试验的比例
0.0%
占全球论文的比例
0.1%
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 1120242025: 222025

这些论文过半是实验室或动物研究。

PubMed 检索ClinicalTrials.gov

神经母细胞瘤

Neuroblastoma
0.2%中国的神经母细胞瘤研究论文,每100篇由它牵头的不到1篇

2021–2025年中国大陆共有 1,132 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。

横条是和占比最高的机构(8.8%)相比。

打开这条 PubMed 检索

牵头的开放试验
0
牵头的研究论文
2
牵头的试验
0
占中国试验的比例
0.0%
占全球论文的比例
0.05%
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

计入的医院

  1. 重庆大学附属肿瘤医院1
  2. 重庆大学附属三峡医院1

2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。

PubMed 检索ClinicalTrials.gov

多发性骨髓瘤

Multiple myeloma
0.3%中国的多发性骨髓瘤研究论文,每100篇由它牵头的不到1篇

2021–2025年中国大陆共有 1,676 篇该病的 PubMed 英文论文,这里牵头了其中 5 篇(第一或最后作者的第一单位是这里)。

横条是和占比最高的机构(4.8%)相比。

打开这条 PubMed 检索

牵头的开放试验
0
牵头的研究论文
5
牵头的试验
2
占中国试验的比例
0.4%
占全球论文的比例
0.05%
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 2220242025: 112025
研究主题诊断、微小残留病与危险分层干细胞移植肾脏与骨骼并发症

计入的医院

  1. 重庆大学附属三峡医院 计入集团统计2
  2. 重庆大学附属肿瘤医院2
  3. 重庆大学附属三峡医院 计入集团统计1
  4. Fuling Hospital, Chongqing University1

2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。

牵头的论文5
  1. Analysis of influencing factors of pulmonary infection during chemotherapy in patients with multiple myeloma and construction of a nomogram prediction model.2025Clinics (Sao Paulo, Brazil)免费全文
  2. Predictive model of the efficiency of hematopoietic stem cell collection in patients with multiple myeloma and lymphoma based on multiple peripheral blood markers.2024International journal of laboratory hematology
  3. XGBoost-based multiparameters from dual-energy computed tomography for the differentiation of multiple myeloma of the spine from vertebral osteolytic metastases.2023European radiology
  4. Identification and prognostic analysis of metabolic genes associated with TP53 mutation in multiple myeloma.2024Hematology (Amsterdam, Netherlands)
  5. miR-26 inhibits proliferation and promotes apoptosis of multiple myeloma cells by targeting BNIP3.2023Cellular and molecular biology (Noisy-le-Grand, France)
ClinicalTrials.gov 上的试验6
  1. A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors正在招募NCT07179679研究中心I期2025-12 启动
  2. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  3. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma正在招募NCT04973605研究中心I/II期2021-09 启动
  4. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments正在招募NCT05020236研究中心III期2021-10 启动
  5. Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells状态不明NCT06026995牵头方IV期2022-03 启动
  6. Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma状态不明NCT06060080牵头方不分期2022-04 启动

PubMed 检索ClinicalTrials.gov

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis
0.3%中国的肌萎缩侧索硬化症研究论文,每100篇由它牵头的不到1篇 ▼ 原为 0.8%

2021–2025年中国大陆共有 779 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。

横条是和占比最高的机构(8.3%)相比。

打开这条 PubMed 检索

牵头的开放试验
0
牵头的研究论文
2
牵头的试验
0
占中国试验的比例
0.0%
占全球论文的比例
0.03%
每年牵头的论文数
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

计入的医院

  1. 重庆大学附属肿瘤医院2

2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。

PubMed 检索ClinicalTrials.gov